Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
This article separates marketing claims from science
Clin Nephrol
Watch the Recording What Youll Learn Current payer perspectives on GLP-1 coverage for obesity treatment and type 2 diabetes management Emerging affordability thresholds and price sensitivity among plans Strategies for addressing off-label type 2 diabetes GLP-1 use and its financial impact Approaches to prior authorization protocols and BMI requirements for obesity GLP-1s The role of weight management vendors in comprehensive obesity GLP-1 coverage strategies Market insights on compounded GLP-1 products and their place in benefit design Attendees will gain actionable strategies and insights to optimize their pharmacy benefit design for these high-impact medications in 2025 and beyond
It referenced a new Lancet study showing that postmenopausal women treated with tirzepatide plus menopausal hormone therapy lost about 35% more weight than those treated with tirzepatide alone
What works better for a lot of us is spreading it out, soft, gentle protein in small bits throughout the day
While most patients remained on AOM tirzepatide, 8.0% switched to AOM semaglutide during this period
US$ 21.18
US$ 28.17
US$ 22.46
US$ 25.32
US$ 27.88
US$ 27.65
